Metraipolis › archive › dc_ede2bda8dc56

Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability — Europe PMC PMID:42490928

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42490928
DOI: 10.3389/fonc.2026.1768842
License (as archived): solo-consultazione
Archived: 2026-10-06T14:32:08.529Z
SHA-256 of the archived text: 33f8bf03c87f9151d461fe3cb9e53110be50b4328044233797f6586a49da8221
Stable URL of this page: https://metraipolis.com/documento/dc_ede2bda8dc56

How to cite

Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability — Europe PMC PMID:42490928 — Europe PMC (en), https://europepmc.org/article/MED/42490928 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ede2bda8dc56 (Metraipolis archive dc_ede2bda8dc56, sha256 33f8bf03c87f9151d461fe3cb9e53110be50b4328044233797f6586a49da8221)

BibTeX

@misc{dcede2bda8dc56,
  title = {Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability — Europe PMC PMID:42490928},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42490928},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ede2bda8dc56; sha256 33f8bf03c87f9151d461fe3cb9e53110be50b4328044233797f6586a49da8221},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42490928. Agents can read the archived copy with the MCP tool read_document.